Lucid Diagnostics Inc (NAS:LUCD)

Q1 2026 Lucid Diagnostics Inc Earnings Call Transcript

May 14, 2026 / 12:30 PM GMT

Release Date Price: $1.02

Transcript 8-K10-Q

Key Points

Positve

Lucid Diagnostics Inc (LUCD) performed 3,177 e-cigar tests in Q1 2026, exceeding their target range of 2,500 to 3,000 tests.
The company successfully raised approximately $16.8 million through a public offering, bolstering their balance sheet to $45 million in pro forma cash.
Lucid Diagnostics Inc (LUCD) has secured a federal supply schedule contract with the VA, allowing them to engage with individual VA centers.
The company is actively engaging with commercial payers and laboratory benefit managers, with expectations of securing more coverage policies.
Lucid Diagnostics Inc (LUCD) had a strong presence at the DDW conference, receiving positive feedback and attention for their eSigard test.

Negative

Revenue for Q1 2026 was $1.3 million, which was slightly down due to a decrease in test volume.
The company is facing delays in obtaining Medicare coverage, which impacts 40-50% of their addressable patient population.
There is volatility in revenue recognition due to the transitional stage of their reimbursement process.
The company has not yet reached a significant level of contracted covered lives with commercial payers.
Lucid Diagnostics Inc (LUCD) is experiencing logistical delays with local coverage determinations, affecting their reimbursement timeline.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LUCD.OQ - Lucid Diagnostics Inc
Q1 2026 Lucid Diagnostics Inc Earnings Call
May 14, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning, and welcome to the Lucid Diagnostics First Quarter 2026 Business Update Conference Call.

Please note that this event is being recorded. I would now like to turn the conference over to Matt Riley, Lucid Diagnostics Vice President of Investor Relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and good morning, everyone.

Thank you for participating in today's business update call. Joining me today on the call are Dr. LeShawn Aklog, Chairman and Chief Executive Officer of Lucid Diagnostics, along with

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.